The theme of this third edition will be “Enhancing Predictivity in Medicines Development” and will focus on bringing together the latest approaches to increase chances of success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.
The programme in a nutshell
The conference will start on Sunday, September 24 with a series of educational workshops. The workshops will be dedicated to key topics in the ﬁeld such as molecular imaging, biomarker validation or potency assays for ATMP’s and vaccines. Read more about the educational workshops. Please note that space is limited to 25 persons per workshop and registration is on first-come, first-serve basis.
For the main conference on September 25 and 26, the event will be structured around 3 plenary sessions, introduced by keynote speakers:
Session 1: The Funder, Developer and Regulator as Partners in Innovation
Session 2: Novel approaches in clinical development
Session 3: Developing more predictive preclinical tools to better reach proof of concept
For this year’s edition, you will hear from – among others – Mark Schmidt (Senior Director, Janssen Research and Development), Philip Murphy (Head, Experimental Medicine Imaging, GSK), Christopher Austin (NIH-NCATS, United States). Find out all about the keynote speakers.